The key role of IFN-γ in HLH pathogenesis, and its activity relatively high up the cytokine cascade, makes it a particularly attractive target for HLH therapy, and this has been borne out in early reports of its real-world use (albeit largely in primary HLH) [79]. Here, IFNG is linked to hemophagocytic syndrome.